Skip to content

Crinetics Pharmaceuticals CRNX Non-Cash Lease Expense

Non-Cash Lease Expense at other companies

Viking Therapeutics logo
Viking TherapeuticsVKTX
$85K-23.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$1.47M+47.5%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$1.76M-1.6%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$2M0.0%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$3.79B+21.9%

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's non-cash lease expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Crinetics Pharmaceuticals's non-cash lease expense?
Crinetics Pharmaceuticals (CRNX) reported non-cash lease expense of $703K in Q1 2026.
How has Crinetics Pharmaceuticals's non-cash lease expense changed year-over-year?
Crinetics Pharmaceuticals's non-cash lease expense decreased by 13.5% year-over-year, from $813K to $703K.
What does non-cash lease expense mean?
Non-cash portion of operating lease cost — the difference between straight-line lease expense and actual cash rent payments.